Zoekresultaten - Eric Gauthier

  • Toon 1 - 13 resultaten van 13
Verfijn jouw resultaten
  1. 1
    Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial

    Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial door Véronique Dièras, Nadia Harbeck, Anil A. Joy, Karen A. Gelmon, Johannes Ettl, Sunil Verma, Dongrui R. Lu, Eric Gauthier, Patrick Schnell, A. Mori, Hope S. Rugo, Richard S. Finn

    Gepubliceerd in 2019
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer

    Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer door Chandrasekar Durairaj, Ana Ruiz‐García, Eric Gauthier, Xin Huang, Dongrui R. Lu, Justin T. Hoffman, Richard S. Finn, Anil A. Joy, Johannes Ettl, Hope S. Rugo, Jenny Zheng, Keith D. Wilner, Diane D. Wang

    Gepubliceerd in 2018
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer

    Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer door Richard S. Finn, Yuan Liu, Zhou Zhu, Miguel Martín, Hope S. Rugo, Véronique Dièras, Seock‐Ah Im, Karen A. Gelmon, Nadia Harbeck, Dongrui R. Lu, Eric Gauthier, Cynthia Huang Bartlett, Dennis J. Slamon

    Gepubliceerd in 2019
    Volledige tekst
    Carta
    Toevoegen aan favorieten
    Bewaard in:
  4. 4
    Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)

    Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast... door RS Finn, Yuqiu Jiang, Hope S. Rugo, SL Moulder, S.-A. Im, Karen A. Gelmon, Véronique Dièras, Miguel Martín, Anil A. Joy, Masakazu Toi, Eric Gauthier, Dongrui R. Lu, Cynthia Huang Bartlett, DJ Slamon

    Gepubliceerd in 2016
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  5. 5
    Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up

    Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breas... door Richard S. Finn, Hope S. Rugo, Karen A. Gelmon, Massimo Cristofanilli, Marco Colleoni, Sherene Loi, Patrick Schnell, Dongrui R. Lu, Kathy Puyana Theall, A. Mori, Eric Gauthier, Eustratios Bananis, Nicholas C. Turner, Véronique Dièras

    Gepubliceerd in 2021
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  6. 6
    Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer

    Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer door Véronique Dièras, Hope S. Rugo, Patrick Schnell, Karen A. Gelmon, Massimo Cristofanilli, Sherene Loi, Marco Colleoni, Dongrui R. Lu, A. Mori, Eric Gauthier, Cynthia Huang Bartlett, Dennis J. Slamon, Nicholas C. Turner, Richard S. Finn

    Gepubliceerd in 2018
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  7. 7
    Sorafenib in patients with progressive epithelioid hemangioendothelioma

    Sorafenib in patients with progressive epithelioid hemangioendothelioma door Christine Chevreau, Axel Le Cesne, Isabelle Ray‐Coquard, Antoîne Italiano, Angela Cioffi, Nicolás Isambert, Y Robin, Charles Fournier, Stéphanie Clisant, L. Chaigneau, Jacques‐Olivier Bay, Emmanuelle Bompas, Eric Gauthier, Jean‐Yves Blay, Nicolas Penel

    Gepubliceerd in 2013
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  8. 8
    Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

    Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up door Hope S. Rugo, Richard S. Finn, Véronique Dièras, Johannes Ettl, O. N. Lipatov, Anil A. Joy, Nadia Harbeck, Aurelio Castrellon, Shrividya Iyer, Dongrui R. Lu, A. Mori, Eric Gauthier, Cynthia Huang Bartlett, Karen A. Gelmon, Dennis J. Slamon

    Gepubliceerd in 2019
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  9. 9
    Palbociclib and Letrozole in Advanced Breast Cancer

    Palbociclib and Letrozole in Advanced Breast Cancer door Richard S. Finn, Miguel Martín, Hope S. Rugo, Stephen E. Jones, Seock‐Ah Im, Karen A. Gelmon, Nadia Harbeck, O. N. Lipatov, Janice M. Walshe, Stacy Moulder, Eric Gauthier, Dongrui R. Lu, Sophia Randolph, Véronique Dièras, Dennis J. Slamon

    Gepubliceerd in 2016
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  10. 10
    Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study

    Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study door Seock-Ah Im, Hirofumi Mukai, In Hae Park, Norikazu Masuda, Chikako Shimizu, Sung-Bae Kim, Young-Hyuck Im, Shoichiro Ohtani, Cynthia Huang Bartlett, Dongrui R. Lu, Shrividya Iyer, Yuko Mori, A. Mori, Eric Gauthier, Richard S. Finn, Masakazu Toi

    Gepubliceerd in 2019
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  11. 11
    Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

    Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer door Dennis J. Slamon, Véronique Dièras, Hope S. Rugo, Nadia Harbeck, Seock‐Ah Im, Karen A. Gelmon, O. N. Lipatov, Janice M. Walshe, Miguel Martín, Mariana Chávez‐MacGregor, Eustratios Bananis, Eric Gauthier, Dongrui R. Lu, Sindy Kim, Richard S. Finn

    Gepubliceerd in 2024
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  12. 12
    Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)

    Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO) door Isabelle Ray‐Coquard, Antoîne Italiano, Emmanuelle Bompas, Axel Le Cesne, Y Robin, Christine Chevreau, Jacques‐Olivier Bay, Guilhem Bousquet, Sophie Piperno‐Neumann, Nicolás Isambert, L. Lemaître, Charles Fournier, Eric Gauthier, Olivier Collard, Didier Cupissol, Stéphanie Clisant, Jean‐Yves Blay, Nicolas Penel

    Gepubliceerd in 2012
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  13. 13
    Talazoparib in Patients with a Germline <i>BRCA</i>-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

    Talazoparib in Patients with a Germline <i>BRCA</i>-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial door Sara A. Hurvitz, Anthony Gonçalvès, Hope S. Rugo, Kyung-Hun Lee, Louis Fehrenbacher, Lida A. Mina, Sami Diab, Joanne L. Blum, Jayeta Chakrabarti, Mohamed Elmeliegy, Liza DeAnnuntis, Eric Gauthier, Akos Czibere, Iulia Cristina Tudor, Ruben G.W. Quek, Jennifer K. Litton, Johannes Ettl

    Gepubliceerd in 2019
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: